CPG3 Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline

Program: Clinical Practice Guidelines
Clinical Session
Sunday, March 8, 2015: 10:15 AM-11:15 AM
Hall G (San Diego Convention Center)
**This session is eligible for CME credit**

Supported by Corcept Therapeutics Incorporated, Noven Pharmaceuticals, Inc. and Pfizer, Inc.

Moderator:
Lawrence Steven Kirschner, MD, PHD, Ohio State Univ, Columbus, OH
Chair:
Lynnette K Nieman, MD, National Institutes of Health, Bethesda, MD
Task Force Participants:
Beverly MK Biller, MD, FACP, Massachusetts General Hospital/Harvard Medical School, Boston, MA , James W Findling, MD, Medical College of Wisconsin, Menomonee Falls, WI , John David Charles Newell-Price, MD, PhD, FRCP, Univ of Sheffield, Sheffield, United Kingdom and Antoine Tabarin, MD, Universite de Bordeaux, Pessac, France

Disclosures:
LKN: Editor, Up To Date, Clinical Researcher, HRA Pharma. LSK: Advisory Group Member, Corcept, Speaker Bureau Member, Pfizer, Inc.. BMB: Principal Investigator, Cortendo, Consultant, Novartis Pharmaceuticals, Principal Investigator, Novartis Pharmaceuticals, Consultant, Cortendo, Consultant, HRA Pharma. JWF: Consultant, Corcept, Investigator, Novartis Pharmaceuticals. JDCN: Investigator, Novartis Pharmaceuticals, Advisory Group Member, Novartis Pharmaceuticals, Consultant, HRA Pharma, Investigator, HRA Pharma. AT: Speaker, Ipsen, Investigator, Novartis Pharmaceuticals, Advisory Group Member, Novartis Pharmaceuticals, Advisory Group Member, Ipsen, Speaker, Novartis Pharmaceuticals, Advisory Group Member, HRA Pharma, Speaker, HRA Pharma.